Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

News

17 August 2017

Evolocumab Phase 3 Cognitive Function Study Results Published in the New England Journal of Medicine

Cambridge Cognition and Amgen announce that the New England Journal of Medicine (NEJM) published results from the evolocumab cognitive function trial, which was conducted in a subset of patients enrolled in the randomized, placebo-controlled evolocumab cardiovascular outcomes study.

Cambridge Cognition and Amgen announce that the New England Journal of Medicine (NEJM) published results from the evolocumab cognitive function trial (EBBINGHAUS, ClinicalTrials.gov Identifier: NCT02207634), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled evolocumab cardiovascular outcomes study (FOURIER, ClinicalTrials.gov Identifier: NCT01764633).

For more information, please see the full Press Release from Amgen 

View the publication at www.nejm.org: Cognitive Function in a Randomized Trial of Evolocumab

Cognitive function was assessed in the EBBINGHAUS study by Cambridge Cognition’s CANTAB® cognitive assessments. CANTAB is an established, language- and culture-independent, computerized, digital cognitive assessment tool that uses touchscreen neuropsychological tests of cognition specifically designed to assess central nervous system disorders and cognitive function across a range of domains, including episodic and working memory, executive function, psychomotor speed and attention.

The results from this study were initially presented at the American College of Cardiology 66th Annual Scientific Session (ACC.17) in March 2017.

For more information about CANTAB cognitive assessment tools to evaluate drug safety and efficacy, please see: www.cambridgecognition.com/clinicaltrials.

 

Reference:

Giugliano, R., Mach, F., Zavitz, K., Kurtz, C., Kyungah, I., & Kanevsky, M. et al. (2017). Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med 2017; 377:633-643August 17, 2017DOI: 10.1056/NEJMoa1701131

For further information about the study protocol, you may also be interested in reading the following paper:

Giugliano R.P., et al. (2017) Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy—A cognitive study of patients enrolled in the FOURIER trial. Clinical Cardiology, 2017. Feb;40(2):59-65. doi: 10.1002/clc.22678. Epub 2017 Feb 16. http://onlinelibrary.wiley.com/doi/10.1002/clc.22678/full